About Ansa Biotechnologies
Ansa Biotechnologies is a company based in Berkeley (United States) founded in 2017 by Sebastian Palluk, Jared Ellefson, and Daniel Lin-Arlow. Ansa Biotechnologies has raised $175.5 million across 8 funding rounds from investors including Mubadala, RA Capital and Northpond Ventures. Ansa Biotechnologies offers products and services including DNA Synthesis Service and Ansa On-Time Guarantee. Ansa Biotechnologies operates in a competitive market with competitors including Twist Bioscience, Nuclera Nucleics, Nutcracker Therapeutics, DNA Script and Sensible Biotechnologies, among others.
- Headquarter Berkeley, United States
- Founders Sebastian Palluk, Jared Ellefson, Daniel Lin-Arlow
- SectorsHealthcare
- Email••••••••
- Website ansabio.com
- Social LinkedIn X YouTube
- Total Equity Funding$175.5M (USD)
in 8 rounds
- Latest Funding Round$54.4M (USD), Series B
Oct 2025
- InvestorsMubadala
& 16 more
Products & Services of Ansa Biotechnologies
Ansa Biotechnologies offers a comprehensive portfolio of products and services, including DNA Synthesis Service and Ansa On-Time Guarantee.
Enables direct synthesis of complex DNA sequences up to 7.5 kb.
Ensures timely delivery of DNA orders or offers free service.
Apps and channels of Ansa Biotechnologies
its YouTube channel Ansa Biotechnologies has 19 subscribers and 7 videos.
Videos from Ansa Biotechnologies
The most watched videos on Ansa Biotechnologies's YouTube channel, Ansa Biotechnologies (19 subscribers). Click a video to play it here.
More on Ansa Biotechnologies.
Funding Insights of Ansa Biotechnologies
Ansa Biotechnologies has successfully raised a total of $175.5M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $54.4 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $175.5M
- Total Rounds 8
- Last Round Series B — $54.4M
- Investors Count 17
All 8 funding rounds of Ansa Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $54.4M | Series B | – | Cerberus Capital Management | |
| Jun 2024 | $45.2M | Series A | – | – | – |
| Apr 2022 | – | Debt – Conventional | – | – | – |
| Apr 2022 | $68M | Series A | – | Northpond Ventures | |
| Apr 2021 | – | Grant | – | – | |
| Jul 2020 | $7.9M | Seed | – | Horizons Ventures | |
| Jul 2019 | $225,000 | Grant | – | – | |
| Dec 2018 | – | Seed | – | Fifty Years | – |
17 investors in total: 17 institutional.
Investors in Ansa Biotechnologies
Ansa Biotechnologies has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Mubadala, RA Capital and Northpond Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life sciences & tech sectors | – | npv.vc | Cambridge, United States | |
Early stage life sciences sectors focused VC firm investing in the US | – | altitudelsv.com | Kirkland, United States | |
Investment firm focused on finance and technology opportunities. | – | peak6.com | - | |
Early-stage companies in science and technology are supported by Humboldt Fund. | 2020 | humboldtfund.com | - | |
- | – | codoncapital.com | - | |
Venture capital firm focused on multiple sectors | – | fiftyyears.com | San Francisco, United States | |
Horizons Ventures is focused on investing in deep science and technology. | – | horizonsventures.com | Hong Kong, China | |
Venture capital fund backed by the US Government | – | seedfund.nsf.gov | Alexandria, United States | |
Private equity and debt firm focused on multiple sectors | – | cerberus.com | New York, United States | |
Blue Water Life Science Advisors is involved in life sciences. | – | bluewaterlifescienceadvisors.com | - |
Investor details for Ansa Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ansa Biotechnologies
20 people are tracked at Ansa Biotechnologies (10 in leadership, 10 in team).
| Name | Role | Group |
|---|---|---|
Sebastian Palluk | Co-Founder & CTO | Leadership |
Jared Ellefson | Co-Founder | Leadership |
Daniel Lin-Arlow | Co-Founder & CSO | Leadership |
Jason T Gammack | CEO | Leadership |
Eric Estrin | Head, Biochemistry | Leadership |
Luke Witt | Director, Laboratory Automation | Leadership |
Shab Vellani | Sr. Director, Sales & Strategic Accounts | Leadership |
Aaron Feldman | Head, Chemistry | Leadership |
Graeme McLean | Head Of Business Development | Leadership |
Mike Demayo | Senior Vice President Of Global Sales And Support | Leadership |
Sassan Sheikholeslami | Principal Scientist, Surface Chemistry | Team |
Haronson Obaara | Scientist | Team |
Nora Ramos | Lab Assistant, Operations | Team |
Chris Hoff | Senior Scientist | Team |
Renhao Zhang | Senior Manufacturing Associate (synthesis) | Team |
Cagsar Apaydin | Lab Manager | Team |
Tan Li | Senior Staff Scientist | Team |
Madison McGowan | Sr. Associate Researcher | Team |
Melissa Thornton | Research Associate | Team |
Isa Harrison | Research Associate | Team |
Complete people profiles for Ansa Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ansa Biotechnologies
3 dated milestones of Ansa Biotechnologies across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Ansa Biotechnologies is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $54.4M.
Competitors of Ansa Biotechnologies
Ansa Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Twist Bioscience, Nuclera Nucleics, Nutcracker Therapeutics, DNA Script and Sensible Biotechnologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| twistbioscience.com | 2013 | San Francisco, United States | $245.81M | 919 | Synthetic DNA is synthesized via a semiconductor-based platform. | |
| nuclera.com | 2013 | Cambridge, United Kingdom | $164.2M | 134 | Desktop bioprinter for genes and proteins production is developed. | |
| nutcrackerx.com | 2018 | Emeryville, United States | $227.04M | – | mRNA therapeutics are developed via proprietary biochip platforms. | |
| dnascript.com | 2014 | Paris, France | $301.69M | – | Benchtop DNA printers for nucleic acid synthesis are developed. | |
| sensible.bio | 2021 | Wilmington, United States | $4.33M | – | Developer of mRNA technology for therapeutics and vaccines | |
| synplechem.com | 2016 | Zurich, Switzerland | $10,200 | – | Automated chemical synthesizers are developed using reagent capsules. | |
| oriciro.com | 2018 | Tokyo, Japan | $10.87M | – | Technologies for DNA synthesis and amplification are developed. | |
| mesabiotech.com | 2009 | San Diego, United States | $26.8M | 131 | Point-of-care molecular diagnostic kits are developed and supplied. | |
| cambriangenomics.com | 2011 | San Francisco, United States | $11.23M | – | Developers of technology for laser printing DNA |
Detailed competitors of Ansa Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ansa Biotechnologies
The website of Ansa Biotechnologies (ansabio.com) receives about 18.5K visits a month.
- Monthly visits18.5K
▼ 22.4% vs previous month
Websites whose visitors overlap most with Ansa Biotechnologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| leidos.com | 100% | 653.3K | #67,417 | View details |
Latest news on Ansa Biotechnologies
Complete news archive for Ansa Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Ansa Biotechnologies
10 companies that operate in the same segment as Ansa Biotechnologies (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ansa Biotechnologies
Ansa Biotechnologies was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Ansa Biotechnologies is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Jason T Gammack is the current CEO of Ansa Biotechnologies.
Ansa Biotechnologies is a funded company, having raised a total of $175.5M across 8 funding rounds to date.
Ansa Biotechnologies was founded in 2017 in Berkeley, United States. Operations are conducted in the biotechnology sector, where DNA synthesis is facilitated through enzyme-based methods. A chemical approach and next-generation technology are utilized, relying on polymerase-nucleotide conjugates to extend DNA molecules by one building block sequentially. Services are centered on advancing molecular synthesis capabilities in a research-oriented environment.
Ansa Biotechnologies's top competitors include Nuclera Nucleics, Twist Bioscience and Sensible Biotechnologies.
Ansa Biotechnologies offers DNA Synthesis Service and Ansa On-Time Guarantee.
Ansa Biotechnologies has 17 investors. Key investors include Mubadala, RA Capital, Northpond Ventures, Altitude Life Science Ventures, and PEAK6.